Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.39 |
| ▸ | TERT | O14746 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3024378 | 1.00 | RORC (0.43) | RORCKDM4EPDE4BNAMPTHSD11B1 | |
| SCHEMBL3023828 | 1.00 | RORC (0.43) | RORCKDM4EPDE4BNAMPTHSD11B1 | |
| SCHEMBL3027132 | 0.88 | RORC (0.43) | RORCKDM4EPDE4BNAMPTDDB1 | |
| SCHEMBL3027134 | 0.88 | RORC (0.43) | RORCKDM4EPDE4BNAMPTDDB1 | |
| SCHEMBL3018279 | 0.87 | PDE4B (0.47) | RORCKDM4EPDE4BNAMPT | |
| SCHEMBL3018278 | 0.87 | PDE4B (0.47) | RORCKDM4EPDE4BNAMPT | |
| SCHEMBL3023568 | 0.86 | RORC (0.41) | RORCKDM4EPDE4BNAMPTDDB1 | |
| SCHEMBL3025951 | 0.86 | KDM4E (0.43) | RORCKDM4EPDE4BNAMPTDDB1 | |
| SCHEMBL3025953 | 0.86 | KDM4E (0.43) | RORCKDM4EPDE4BNAMPTDDB1 | |
| SCHEMBL3023565 | 0.86 | RORC (0.41) | RORCKDM4EPDE4BNAMPTDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210680-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. ORGANON | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210680-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | TPH1, HTR2C, TPH2 | RORC 1536/4885KDM4E 2053/4885PDE4B 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.